Literature DB >> 33517605

The clinical outcomes of fresh versus frozen embryos transfer in women ≥40 years with poor ovarian response.

Conghui Liu1, Yu Li1, Hong Jiang1, Yingchun Liu1, Xiaomin Song1.   

Abstract

OBJECTIVE: To compare the clinical outcomes of fresh embryo transfers (ETs) and frozen-thawed embryo transfers (FETs) after a freeze-all cycle in women ≥40 years old with poor ovarian response (POR).
METHODS: We performed a single-center, retrospective, case-control study of patients who underwent in vitro fertilization between January 2014 and June 2019. We included a total of 192 patients aged 40 years or older from whom 3 or fewer oocytes had been retrieved and who were receiving cleavage-stage ET in this study. Of these patients, 101 and 91 patients underwent fresh ET and FET, respectively. The primary outcome was the live birth rate (LBR) after the first ET. Logistic regression analysis was used to compare the IVF outcomes and neonatal characteristics between the fresh ET and FET groups, adjusting for maternal age, body mass index, luteinizing hormone, and the number of good quality embryos transferred.
RESULTS: The mean maternal ages and number of oocytes retrieved (43.2 years and 2.3 in both groups, P=0.902 and P=0.927, respectively) were similar in the fresh ET and FET groups. No significant difference was observed between the LBRs of the fresh ET and FET groups (adjusted odds ratio, 1.28; 95% confidence interval, 0.29-5.70). The clinical pregnancy and miscarriage rates, and neonatal characteristics (birth weights and premature infant rates) were similar between the 2 groups.
CONCLUSION: s FET after the freeze-all strategy had no beneficial impact on the clinical outcomes of women ≥40 years with POR.

Entities:  

Keywords:  Cryopreservation; Embryo transfer; In vitro fertilization; Infertility; Maternal age

Year:  2021        PMID: 33517605     DOI: 10.5468/ogs.20124

Source DB:  PubMed          Journal:  Obstet Gynecol Sci        ISSN: 2287-8572


  1 in total

1.  Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination.

Authors:  Binarwan Halim; Hilma Putri Lubis
Journal:  Obstet Gynecol Sci       Date:  2022-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.